No­var­tis takes aim at a slate of block­busters with cheap­er biosim­i­lars

No­var­tis stepped in as one of the ear­ly pi­o­neers in de­vel­op­ing new biosim­i­lars. And now the Swiss phar­ma gi­ant has out­lined its game plan to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.